Adding Merck KGaA's Erbitux to chemo helps to fight bowel cancer

25 April 2016

A Chinese Phase III study has met its primary endpoint in significantly increasing progression-free survival (PFS) in bowel cancer patients treated with Erbitux (cetuximab) plus Folfox chemotherapy, compared with the latter alone.

German's Merck KGaA welcomed the results of the Tailor study, supporting other evidence it has provided of its Erbitux antibody in combination with Folfox as a standard first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).

Erbitux has already obtained market authorization in over 90 countries worldwide for colorectal cancer and Merck KGaA will work with relevant authorities to make it available for patients in China as a first-line treatment as soon as possible.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK